Virax Biolabs Closes $5 Million Private Placement to Extend Cash Runway
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Source: PRnewswire
- Successful Financing: Virax Biolabs has successfully closed a $5 million private placement, issuing 12.5 million ordinary shares and preferred investment options, reflecting market confidence in its immunology research.
- Clear Use of Funds: The proceeds from this financing will be used for general working capital, extending the company's cash runway into the first half of 2028, ensuring continued progress in its post-acute sequelae of COVID-19 studies.
- Registration Statement Commitment: Virax has committed to filing a registration statement with the SEC within 45 days to facilitate the resale of securities, enhancing investor confidence and liquidity.
- Adjustment of Preferred Investment Options: The company is reducing the exercise price of existing preferred investment options from $2.934 to $0.40, further lowering the entry barrier for investors and promoting future financing activities.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like VRAX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on VRAX
Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.290
Low
1.00
Averages
1.00
High
1.00
Current: 0.290
Low
1.00
Averages
1.00
High
1.00
About VRAX
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Virax Biolabs Closes $5 Million Private Placement to Extend Cash Runway
- Successful Financing: Virax Biolabs has successfully closed a $5 million private placement, issuing 12.5 million ordinary shares and preferred investment options, reflecting market confidence in its immunology research.
- Clear Use of Funds: The proceeds from this financing will be used for general working capital, extending the company's cash runway into the first half of 2028, ensuring continued progress in its post-acute sequelae of COVID-19 studies.
- Registration Statement Commitment: Virax has committed to filing a registration statement with the SEC within 45 days to facilitate the resale of securities, enhancing investor confidence and liquidity.
- Adjustment of Preferred Investment Options: The company is reducing the exercise price of existing preferred investment options from $2.934 to $0.40, further lowering the entry barrier for investors and promoting future financing activities.
Continue Reading
Virax Biolabs Secures $5 Million Funding to Extend Cash Runway into 2028
- Successful Financing: Virax Biolabs has successfully closed a $5 million private placement, issuing 12.5 million ordinary shares and preferred investment options, which is expected to extend its cash runway into the first half of 2028, ensuring continued operations in COVID-19 sequelae research.
- Research Advancement: The funding will support Virax in completing its US and UK studies on post-acute sequelae of COVID-19, with plans to submit applications to the FDA and MHRA, further driving innovation in immunology.
- Investor Confidence: The involvement of H.C. Wainwright & Co. as the exclusive placement agent indicates strong market confidence in Virax's future growth, with the successful financing enhancing the company's competitiveness in the biotechnology sector.
- Equity Structure Adjustment: Virax will also reduce the exercise price of existing preferred investment options from $2.934 to $0.40 and extend their term to five years, aiming to increase investor participation and optimize its capital structure.
Continue Reading